<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> is a once-daily, orally administered, tridentate iron <z:chebi fb="0" ids="38161">chelator</z:chebi> that is indicated in the treatment of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> resulting from regular packed red blood cell transfusions in patients with transfusion-dependent <z:hpo ids='HP_0001903'>anemias</z:hpo>, such as <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e>, <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and other rare <z:hpo ids='HP_0001903'>anemias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Randomized, controlled trials have established its efficacy to reduce liver iron concentration and serum ferritin levels to be comparable to the historic standard iron <z:chebi fb="0" ids="38161">chelator</z:chebi>, <z:chebi fb="0" ids="4356">deferoxamine</z:chebi>, which is administered as a parenteral infusion </plain></SENT>
<SENT sid="2" pm="."><plain>However, <z:chebi fb="0" ids="49005">deferasirox</z:chebi> may be more effective than <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> in actual clinical practice owing to the improvement in quality of life and, hence, increased compliance associated with the oral route of administration </plain></SENT>
<SENT sid="3" pm="."><plain>The higher acquisition cost of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> may be counterbalanced by savings in the administration cost, as well as the treatment of complications of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> that result from noncompliance with therapy attributable to the parenteral mode of administration </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> may also have potential as an important supplement and even an alternative to phlebotomies in nontransfusional, genetic <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> disorders, such as hereditary <z:mp ids='MP_0005638'>hemochromatosis</z:mp> </plain></SENT>
</text></document>